ClinicalTrials HQ

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Active, not recruiting · NCT02402660 · Registry updated 2026-09-21
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 2 Tolerability and Effects of ALK-001 on Stargardt DiseaseCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Stargardt disease, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorderActive, not recruitingPhase 22026-09-21NCT02402660

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Alkeus Pharmaceuticals, Inc.3

14 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Alkeus SiteGainesvilleUnited States2
Alkeus SiteBaltimoreUnited States1
Alkeus SiteWestburyUnited States2
Alkeus SiteMilwaukeeUnited States1
Alkeus SiteSalt Lake CityUnited States1
Alkeus SiteGrand RapidsUnited States1
Alkeus SiteNew YorkUnited States1
Alkeus SiteLos AngelesUnited States2
Alkeus SiteMiamiUnited States1
Alkeus SiteIndianapolisUnited States2
Alkeus SitePhoenixUnited States2
Alkeus SiteHoustonUnited States1
Alkeus SiteAuroraUnited States2
Alkeus SiteSilverdaleUnited States2